JP2013509861A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013509861A5 JP2013509861A5 JP2012536757A JP2012536757A JP2013509861A5 JP 2013509861 A5 JP2013509861 A5 JP 2013509861A5 JP 2012536757 A JP2012536757 A JP 2012536757A JP 2012536757 A JP2012536757 A JP 2012536757A JP 2013509861 A5 JP2013509861 A5 JP 2013509861A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- binding polypeptide
- her3
- her3 binding
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 34
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims 34
- 229920001184 polypeptide Polymers 0.000 claims 33
- 102000004196 processed proteins & peptides Human genes 0.000 claims 33
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 239000003446 ligand Substances 0.000 claims 8
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 5
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 5
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000037845 Cutaneous squamous cell carcinoma Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000014070 Vestibular schwannoma Diseases 0.000 claims 1
- 208000004064 acoustic neuroma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 208000029986 neuroepithelioma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 108020001580 protein domains Proteins 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09175025.7 | 2009-11-04 | ||
| EP09175025 | 2009-11-04 | ||
| PCT/SE2010/051164 WO2011056124A1 (en) | 2009-11-04 | 2010-10-27 | Her3 binding polypeptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013509861A JP2013509861A (ja) | 2013-03-21 |
| JP2013509861A5 true JP2013509861A5 (enExample) | 2013-12-05 |
| JP5960598B2 JP5960598B2 (ja) | 2016-08-02 |
Family
ID=43302000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012536757A Expired - Fee Related JP5960598B2 (ja) | 2009-11-04 | 2010-10-27 | Ｈｅｒ３結合ポリペプチド |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10208128B2 (enExample) |
| EP (1) | EP2496598B1 (enExample) |
| JP (1) | JP5960598B2 (enExample) |
| WO (1) | WO2011056124A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2346178T3 (es) * | 2007-07-31 | 2015-11-02 | Affibody Ab | Nuevas composiciones, procedimientos y usos de unión de la albúmina |
| US20120165650A1 (en) * | 2010-12-22 | 2012-06-28 | General Electric Company | Her2 binders |
| SI2516469T1 (sl) | 2009-12-22 | 2016-05-31 | Roche Glycart Ag | Protitelesa proti her3 in uporabe le-teh |
| AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| JP6101638B2 (ja) | 2011-03-03 | 2017-03-22 | ザイムワークス，インコーポレイテッド | 多価ヘテロマルチマー足場設計及び構築物 |
| WO2013063702A1 (en) | 2011-11-04 | 2013-05-10 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| WO2014004586A1 (en) | 2012-06-25 | 2014-01-03 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
| WO2014012082A2 (en) | 2012-07-13 | 2014-01-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design an constructs |
| JP6440618B2 (ja) * | 2012-10-05 | 2018-12-19 | アフィボディ・アーベー | Ｈｅｒ３結合ポリペプチド |
| AU2013336646B2 (en) | 2012-10-25 | 2016-07-14 | Affibody Ab | ABD binding polypeptide |
| JP6396303B2 (ja) | 2012-10-25 | 2018-09-26 | アフィボディ・アーベー | アルブミン結合を含有するタンパク質の分離方法 |
| US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
| US9957330B2 (en) * | 2012-12-19 | 2018-05-01 | Affibody Ab | Polypeptides |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| CN105209482B (zh) * | 2013-03-15 | 2022-04-29 | 阿菲博迪公司 | 新的多肽 |
| TR201911279T4 (tr) | 2013-08-28 | 2019-08-21 | Affibody Ab | Mutasyona uğramış bir yapı iskelesine sahip polipeptidlerin bağlanması. |
| ES3030987T3 (en) | 2013-11-27 | 2025-07-03 | Zymeworks Bc Inc | Bispecific antigen-binding constructs targeting her2 |
| RS66392B1 (sr) | 2014-02-28 | 2025-02-28 | Merus Nv | Antitelo koje vezuje erbb-2 i erbb-3 |
| ES2816624T3 (es) | 2014-02-28 | 2021-04-05 | Merus Nv | Anticuerpos que se unen a EGFR y ERBB3 |
| CN106255705B (zh) | 2014-05-14 | 2021-01-08 | 豪夫迈·罗氏有限公司 | 结合HER3β-发夹和HER2域II的HER3/HER2双特异性抗体 |
| ES2744588T3 (es) * | 2014-09-17 | 2020-02-25 | Affibody Ab | Nuevos polipéptidos |
| KR20250094744A (ko) * | 2014-12-22 | 2025-06-25 | 시스트이뮨, 인코포레이티드 | 이중특이적 4가 항체 및 이의 제조 및 사용방법 |
| US12428483B2 (en) * | 2014-12-22 | 2025-09-30 | Systimmune, Inc. | Bispecific tetravalent antibodies and methods of making and using thereof |
| CN108137706A (zh) | 2015-07-15 | 2018-06-08 | 酵活有限公司 | 药物缀合的双特异性抗原结合构建体 |
| US11939394B2 (en) | 2015-10-23 | 2024-03-26 | Merus N.V. | Binding molecules that inhibit cancer growth |
| IL269656B2 (en) | 2017-03-31 | 2024-06-01 | Merus Nv | Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene |
| EP3625264B9 (en) | 2017-05-17 | 2023-10-25 | Merus N.V. | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer |
| PL3665198T3 (pl) | 2017-08-09 | 2025-06-09 | Merus N.V. | Przeciwciała wiążące egfr i cmet |
| KR20250047787A (ko) | 2022-08-10 | 2025-04-04 | 교와 가부시키가이샤 | 어피바디 미셀 약물 복합체 |
| WO2024213587A1 (en) * | 2023-04-11 | 2024-10-17 | Antaros Tracer Ab | Drug delivery systems |
| AU2024265436A1 (en) * | 2023-05-04 | 2025-11-06 | Affibody Ab | New polypeptide |
| GB202318674D0 (en) * | 2023-12-06 | 2024-01-17 | Oncopeptides Ab | Novel polypeptides |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US7332580B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US7332585B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| AU2004253835B2 (en) * | 2003-07-04 | 2009-01-29 | Affibody Ab | Polypeptides having binding affinity for HER2 |
| US8642743B2 (en) | 2004-04-06 | 2014-02-04 | Affibody Ab | Method for reducing the immune response to a biologically active protein |
| US8008453B2 (en) * | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| GB0524788D0 (en) * | 2005-12-05 | 2006-01-11 | Affibody Ab | Polypeptides |
| SI2716301T1 (sl) * | 2007-02-16 | 2017-07-31 | Merrimack Pharmaceuticals, Inc. | Protitelesa proti ErbB3 in uporaba le-teh |
| EP2183275B1 (en) * | 2007-08-03 | 2014-10-29 | Affibody AB | Igf-1r binding polypeptides and their use |
| EP2072525A1 (en) | 2007-12-21 | 2009-06-24 | Affibody AB | New polypeptides having affinity for HER2 |
| JP6440618B2 (ja) | 2012-10-05 | 2018-12-19 | アフィボディ・アーベー | Ｈｅｒ３結合ポリペプチド |
| CN106999587B (zh) * | 2014-10-02 | 2023-09-29 | 希望之城公司 | 多价中间表位，中间表位结合抗体及其用途 |
-
2010
- 2010-10-27 WO PCT/SE2010/051164 patent/WO2011056124A1/en not_active Ceased
- 2010-10-27 US US13/505,493 patent/US10208128B2/en active Active
- 2010-10-27 EP EP10775936.7A patent/EP2496598B1/en active Active
- 2010-10-27 JP JP2012536757A patent/JP5960598B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013509861A5 (enExample) | ||
| KR102236829B1 (ko) | 헵시딘 유사체 및 이의 용도 | |
| JP2014508510A5 (enExample) | ||
| NZ602943A (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
| MX2012007850A (es) | Composiciones y metodo para tratar gliobastoma (gbm). | |
| HRP20110551T1 (hr) | Antagonisti cikličkog peptida cxcr4 | |
| JP2013506411A5 (enExample) | ||
| US20170281796A1 (en) | c-Met Antibody Drug Conjugate | |
| JP2016521257A5 (enExample) | ||
| EA201291362A1 (ru) | Слитый белок против злокачественных новообразований | |
| EA200901430A1 (ru) | Варианты фермента аспарагиназы и их применение | |
| RU2016146198A (ru) | Терапевтические dll4-связывающие белки | |
| JP2010534486A5 (enExample) | ||
| JP2017006120A5 (enExample) | ||
| WO2007115837B1 (en) | Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule | |
| JP2013172743A5 (enExample) | ||
| TW201129379A (en) | Anti-Orai1 antigen binding proteins and uses thereof | |
| WO2007123765A3 (en) | Neutrokine-alpha and neutrokine-alpha splice variant | |
| WO2013075600A1 (zh) | 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用 | |
| JP2015508652A5 (enExample) | ||
| JP2017513516A5 (enExample) | ||
| WO2006087637A3 (en) | Anti her2/neu antibody | |
| RU2015141932A (ru) | Аргининдеиминаза с пониженной перекрестной реактивностью к антителам adi-peg 20 для лечения рака | |
| MX2008009493A (es) | Peptido novedoso y uso del mismo. | |
| KR102399024B1 (ko) | 신규 폴리펩티드 |